

Biomatrix Alpha in small vessels.

Fco. Javier Lacunza Ruiz.
Interventional Cardiology Department.
Hospital Universitario Virgen de la Arrixaca.
Murcia. Spain.


Biomatrix Alpha in small vessels.

- **Clinical data:**
 - 65 y.o. man.
 - CVRF: Hypertension, diabetes, smoker.
 - Previous history of ischemic cardiac disease, with 3 vessel disease, treated with IMA to LAD (2002).
 - Referred for effort angina with positive stress test.

Biomatrix Alpha in small vessels.


- Clinical data (II)
 - Right Angiogram:
 - Chronic total occlusion in proximal RCA (small vessel).
 - Left Angiogram (left radial artery):
 - Chronic total occlusion in middle LAD. Patent by-pass from LIMA to distal LAD.
 - Severe stenosis in proximal CX and first marginal (small calcified vessel).

Biomatrix Alpha in small vessels.



- Chronic total occlusion in RCA.


Biomatrix Alpha in small vessels.




➤ Chronic total occlusion in middle LAD.




Biomatrix Alpha in small vessels.




- Severe calcified lesion in first marginal, severely angulated.
- Severe lesion in proximal CX.



Biomatrix Alpha in small vessels.




- Patent LIMA to distal LAD, without flow to the circumflex system.



Biomatrix Alpha in small vessels.


- Initial strategy:
 - 1) Treatment of the first marginal.
 - 2) CX treatment
- High support 6French catheter with left radial approach

Biomatrix Alpha in small vessels.




- AL2 6 French catheter
 - BHW wire to 1st marginal.
 - Sion wire to distal CX.

Biomatrix Alpha in small vessels.




A) 1.5 balloon to 1st marginal.


B) 2.0 balloon to 1st marginal




Biomatrix Alpha in small vessels.




- 2.25 Biomatrix Alpha to 1st marginal.




Biomatrix Alpha in small vessels.



- 2.25 Biomatrix Alpha to 1st marginal.




Biomatrix Alpha in small vessels.




- Pre-dilatation of CX with 3.5 non-compliant ballon.


Biomatrix Alpha in small vessels.



- Withdrawal of the wire of 1st marginal.
- Implant of Biomatrix Alpha 4x19 mm.
- The previous stent is clearly visible with fluoroscopy.



Biomatrix Alpha in small vessels.



➤ Final result.

Biomatrix Alpha in small vessels.

- Small vessel treatment represents a challenging scenario in PCI due to:
 - Difficulties in the access to the vessel
&
 - Poor long term evolution (higher risk of stent restenosis).

Biomatrix Alpha in small vessels.

- The present case is a challenging case due to the combination tortuosity and calcification of the vessel, besides the small size, that always increases difficulty of the procedure.
- *Biomatrix Alpha* has proven to be an excellent option in treating difficult lesion.

Biomatrix Alpha in small vessels.

- Some of the remarkable characteristics of the stent demonstrated in this case are:
 - Excellent deployment capability in calcified and tortuous scenarios.
 - Excellent visibility within the “empty” vessel.

Biomatrix Alpha in small vessels.

- In conclusion, Biomatrix Alpha has demonstrated its adaptation to complex lesion with excellent results.
- The drug and the polymer have demonstrated a safe profile in all scenarios where a DES is needed.